l e t t e r s CBL encodes a member of the Cbl family of proteins, which functions as an E3 ubiquitin ligase. We describe a dominant developmental disorder resulting from germline missense CBL mutations, which is characterized by impaired growth, developmental delay, cryptorchidism and a predisposition to juvenile myelomonocytic leukemia (JMML). Some individuals experienced spontaneous regression of their JMML but developed vasculitis later in life. Importantly, JMML specimens from affected children show loss of the normal CBL allele through acquired isodisomy. Consistent with these genetic data, the common p.371Y>H altered Cbl protein induces cytokine-independent growth and constitutive phosphorylation of ERK, AKT and S6 only in hematopoietic cells in which normal Cbl expression is reduced by RNA interference. We conclude that germline CBL mutations have developmental, tumorigenic and functional consequences that resemble disorders that are caused by hyperactive Ras/Raf/MEK/ERK signaling and include neurofibromatosis type 1, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome and Legius syndrome.
Myeloproliferative neoplasms (MPNs) are clonal malignancies that are characterized by overproduction of immature and mature myeloid lineage cells. Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood MPN that is characterized by malignant transformation in the stem cell compartment with clonal proliferation of progeny that variably retain the capacity to differentiate 1 . Hematopoietic stem cell transplantation (HSCT) is the only cure for JMML; however, relapse rates approach 30% (ref. 2) . Although spontaneous remissions occur in some infants 3, 4 , the underlying mechanism for this is unknown.
Germline and somatic mutations that deregulate Ras signaling are implicated as key initiating events in JMML; 60% of affected individuals harbor an oncogenic mutation in the Ras signaling genes PTPN11, NRAS or KRAS and another 15% have mutations in the neurofibromatosis type 1 (NF1) gene (NF1) and show loss of the normal NF1 allele in leukemic cells [5] [6] [7] [8] [9] . Individuals with the myeloproliferative subtype of chronic myelomonocytic leukemia (CMML), a similar MPN in adults, frequently display NRAS, KRAS and JAK2 mutations 10, 11 . Mouse models recapitulate these diseases, supporting the hypothesis that hyperactive Ras is necessary and sufficient to cause MPN [12] [13] [14] [15] . A hallmark feature of JMML and CMML is the formation of abnormally high numbers of granulocyte-macrophage colonyforming units (CFU-GM) in methylcellulose cultures containing low concentrations of granulocyte-macrophage colony-stimulating factor (GM-CSF) 16, 17 . Phosphorylation of the β c chain of the GM-CSF receptor creates docking sites for adapters and signal relay molecules, resulting in activation of the Ras pathway.
Samples from individuals with MPNs can show copy-neutral loss of heterozygosity (acquired isodisomy) of a region on chromosome 11q and homozygous mutations in CBL [18] [19] [20] [21] . Approximately 10-15% l e t t e r s of children with de novo JMML are estimated to harbor homozygous CBL mutations 20, 22 . CBL mutations are acquired somatically in adults with MPNs 18, 19, 21 .
As children with NF1 and Noonan syndrome are predisposed to JMML 8, 9, [23] [24] [25] , we tested whether germline CBL mutations occur in affected children. Twenty-one children with JMML were found to have CBL mutations (16 of 21 were previously included in a screen of a larger international cohort 20 ) and an unexpectedly high percentage of these children showed developmental delay, cryptorchidism and impaired growth (Tables 1 and 2 ). All children met diagnostic criteria for JMML 26, 27 but six individuals who were followed up for more than seven years did not undergo transplantation for various reasons. Of these, one died of progressive JMML (D088), but the MPN improved spontaneously in five others. All of these subjects continued to show variable degrees of splenomegaly in the presence of normal blood counts and had a persistent homozygous CBL mutation in CD4, CD8, CD14 and CD19 sorted cells from their peripheral blood at their last follow-up. In addition, four of these subjects developed clinical signs consistent with vascular pathology, including optic atrophy, hypertension and an acquired cardiomyopathy; one was diagnosed with Takayasu arteritis, type III by angiography (Fig. 1a) . Another subject (D256) developed an intracranial germinoma harboring the same homozygous CBL mutation as in his bone marrow. Of note, among the patients treated with HSCT, there was a high rate of conversion to stable mixed chimerism (9 of 11 patients for whom data are available; Table 1) .
We analyzed normal tissues from 17 of these children and detected a heterozygous CBL mutation in each. Mutational analysis of parental DNA was informative in 13 families and confirmed autosomal inheritance of a CBL mutation in seven (Fig. 1b,c , Table 2 and Supplementary  Fig. 1 ). Subjects UPN1333 and UPN1125 were from large pedigrees in which several individuals had died of JMML (Fig. 1b,c) .
The proband in family 1 (UPN1333, V:1; Fig. 1b ) was referred after transplantation for JMML. Initially diagnosed at 7 months of age, he received his first HSCT at 13 months and then developed mixed chimerism 6 months later. A blood sample showed a homozygous CBL mutation at c.1111T>C (p.371Y>H). Importantly, analysis of buccal swab DNA revealed a heterozygous lesion. Both maternal relatives died from progressive JMML. Peripheral blood or buccal swabs from extended family members revealed multiple heterozygous individuals (Fig. 1b) . Detailed medical history from the affected maternal greatgrandmother revealed a history of infant leukemia characterized by a high white blood cell count and splenomegaly that resolved spontaneously. Sorted B (CD19) and T (CD3) cells and granulocytes from her peripheral blood showed a heterozygous c.1111T>C mutation. Leukemia cells from UPN1333 showed a classic pattern of GM-CSF hypersensitivity (Fig. 1d) and increased phosphorylation of STAT5 in response to low doses of GM-CSF 28 . Peripheral blood mononuclear cells from his heterozygous mother did not show either of these features, suggesting that homozygosity for the mutant CBL allele is essential for these characteristics (data not shown).
The proband in family 2 ( Fig. 1c ; UPN1125, IV:3) was a girl diagnosed at 15 months of age with JMML. She also harbored a homozygous c.1111T>C CBL mutation in her bone marrow. Family history revealed that her mother had two male first cousins who were diagnosed with JMML and died before age 10. Frozen liver tissue from the first boy was available from autopsy and showed a heterozygous c.1111T>C mutation. Notably, he also developed clinical signs and laboratory test results consistent with small vessel vasculitis before his death. The mother of UPN1125 was found to carry a heterozygous CBL mutation (Fig. 1c) .
Three subjects showed homozygous splice site mutations ( Table 2 ; I066, D647 and D347). RT-PCR showed several new splice products arising from these mutations (Fig. 2) ; most notable are the two splice l e t t e r s site variants that delete either exon 8 (D347) or exon 9 (I066 and D647; Supplementary Fig. 2 ) or retain an interstitial intron (for example, intron 7 for D347). Each of the deletion splice variants encodes a protein that is predicted to lack essential regions of the linker and RING finger domains, whereas the retention of intron 7 introduces a premature stop codon to abort translation upstream of the RING finger domain.
To investigate the functional properties of the mutant Cbl proteins encoded by homozygous point mutations, we first studied the effect of the common p.371Y>H substitution on the growth of primary hematopoietic cells from mouse fetal liver. This system reproduces the hypersensitivity to GM-CSF that is characteristic of JMML 16, 29 . Fetal liver cells transduced with retroviral vectors expressing wild-type or mutant Cbl proteins showed no increased sensitivity to GM-CSF (Fig. 3a) . Similarly, expression of p.371Y>H Cbl in a BaF3-EpoR cell line did not confer cytokine independence (Fig. 3b) . Based on the observation that JMML cells invariably lose the normal CBL allele and on recent findings 21 , we reasoned that reduction of Cbl expression might be mandatory to deregulate hematopoietic growth. Therefore, we introduced a short hairpin RNA, which reduced the expression of mouse Cbl in BaF3-EpoR cell lines (Fig. 3c) . We next transduced these cells with a series of wild-type and mutant human constructs and found that exogenous Cbl was strongly expressed (Fig. 3c) . In this context, we observed cytokine-independent proliferation (Fig. 3d) upon expression of p.371Y>H Cbl or a known mouse oncogenic Cbl protein (70Z) [30] [31] [32] . The 70Z oncogenic protein deletes 17 amino acids from position 366-382 in the linker domain. Furthermore, cells transduced with p.371Y>H or 70Z showed hypersensitivity to increasing concentrations of human EPO (Fig. 3e) , mimicking the growth factor hypersensitivity seen in JMML (Fig. 1d) . In cells depleted of endogenous Cbl and expressing exogenous p.371Y>H or 70Z Cbl proteins, we observed constitutive phosphorylation of ERK, AKT and S6 in cells deprived of cytokine. We also found heightened responses to low doses of EPO (Fig. 3f) .
To determine whether mutant Cbl proteins retain E3 ligase activity, we assessed their ability to promote ubiquitylation of a known Cbl substrate. Soon after activation, the epidermal growth factor receptor (EGFR) undergoes Cbl-dependent polyubiquitylation and proteosomal degradation. HEK293 cells expressing hemagglutinintagged (HA)-Cbl(p.371Y>H) showed markedly elevated levels of phosphorylated EGFR upon EGF stimulation in comparison to cells expressing HA-Cbl(WT) (Fig. 4a) , which indicates a possible defect in clearance of pEGFR by Cbl(p.371Y>H). The Cbl(p.384C>R) mutant showed a similar defect in pEGFR clearance (data not shown). Upon polyubiquitylation of targets, Cbl promotes its own polyubiquitylation and subsequent auto-degradation. Consistent with this model, levels of Cbl(WT), but not of Cbl(p.371Y>H or p.384C>R), rapidly diminished after EGF treatment in the absence of the proteasome inhibitor MG132 (Fig. 4a,b and data not shown,). However, Cbl(WT) levels were stabilized in the presence of MG132 whereas Cbl(p.371Y>H) levels remained relatively high irrespective of MG132 (Fig. 4b) , which suggests that the Cbl mutants p.371Y>H and p.384C>R have an inherent defect in E3 function. Consistent with this notion, Cbl(WT) promoted robust polyubiquitylation of pEGFR whereas p.371Y>H and p.384C>R showed diminished capacity to polyubiquitylate pEGFR in an in vitro ubiquitylation assay (data not shown). This diminished capacity is similar to that of 70Z, which is defective in E3 ligase l e t t e r s activity, and agrees with recent finidings that p.371Y>S and p.367Q>P mutants in human subjects also have diminished ubiquitylation activity 21 . The Y371 residue that is most commonly affected in germline CBL mutations has been the focus of extensive biochemical analysis 21 . This analysis supports the idea that Y371 in essential for maintaining the integrity of the alpha-helical structure of the linker region, which has a critical role in substrate specificity. Notably, Y371 has been found to be phosphorylated despite its predicted location away from the protein surface. Substitution of this residue with phenylalanine results in a non-oncogenic form of the protein, which lacks E3 ligase activity. Conversely, substitution with a glutamate constitutively activates the E3 ligase activity 33, 34 . CBL appears to function as a classic tumor suppressor gene in this cohort, with germline heterozygosity predisposing to neoplasia upon reduction to homozygosity in target tissues. However, the predominance of specific missense mutations makes CBL distinct from most tumor suppressor genes such as RB and NF1, which have more severe loss of function mutations such as deletion or protein truncation. This suggests that the mutant Cbl proteins retain an essential biochemical function 20, 21 , which is supported by our data showing that exclusive expression of a mutant CBL allele has positive effects on cytokine signaling and proliferation. The specific disruption of E3 ligase activity might leave intact adaptor functions, resulting in a relative imbalance of Cbl's role in signal transduction. Sanada et al. hypothesized that this might result in inhibitory effects on Cbl-b, a related family member 21 . This is similar to what has been reported for p53, a classic tumor suppressor gene with specific gain-offunction mutations in the context of loss of heterozygosity 35, 36 . Fig. 1d ). Both father and daughter also show bilateral ptosis. Informed consent to publish the photograph in e was obtained from the subject's father. Fig. 2 for sequences) . Δ, deletions; ins, insertions; *premature stop codons.
l e t t e r s
Beyond missense mutations, truncated Cbl proteins also confer transforming effects by countering the negative action of full-length Cbl on RTK signaling 37 .
Some individuals can experience spontaneous resolution of JMML but later develop clinical features consistent with vasculitis and other autoimmune phenomena. Mice that lack Cbl in T cells develop severe vascular lesions with massive infiltration of T cells and high concentrations of anti-double stranded DNA antibodies 38 . These T cells are hypersensitive to T cell receptor signaling and show prolonged ERK phosphorylation. Similarly, mice that lack Cbl in B cells develop a lupus-like syndrome associated with perivascular infiltration and hyperactivation of B cell receptor signaling 39 . In mice, loss of Cbl-b is required for these phenotypes. Oncogenic Cbl proteins might therefore inhibit Cbl-b in vivo, resulting in a functional loss of both Cbl and Cbl-b, which in turn contributes to dysregulated lymphocyte signaling and subsequent vasculitis. The redundant roles of Cbl and Cbl-b were explored by Sanada et al., who showed that c-Cbl p.371Y>S inhibits wild-type Cbl-b 21 . Individuals with JMML and homozygous CBL mutations who undergo HSCT are not known to develop vasculitis later in life, implying that a normal immune system is essential for preventing this late manifestation.
We describe a new syndrome in which affected children display several congenital anomalies that overlap with NF1, Noonan syndrome and Legius syndrome, suggesting that the affected proteins converge on the Ras/MAPK pathway. Indeed, several Ras/MAPK pathway proteins regulate developmental programs in multiple species: for instance, the Drosophila homologs of each of l e t t e r s these genes (CBL (D-cbl), PTPN11 (csw), NF1 and SPRED) perform crucial functions for growth and patterning [40] [41] [42] [43] .
Individuals with germline CBL mutations are at increased risk of developing JMML, which might follow an aggressive clinical course or resolve without treatment. Some affected individuals develop vasculitis later in life. The CBL mutations found in JMML can arise de novo or can be transmitted through the germline, and human leukemia samples invariably show loss of the normal CBL allele. Consistent with this tumor suppressor function, JMML-associated Cbl proteins confer cytokine hypersensitivity in transduced BaF3-EpoR cells in the absence of wild-type Cbl, have defective E3 ligase activity, and constitutively activate key Ras effector pathways. The role of aberrant Cbl signaling in vasculitis remains to be determined, and it will be interesting to investigate whether individuals with germline CBL mutations who have been cured of JMML after HSCT remain at risk of developing vasculitis. It is also of great interest that some of these individuals continue to show homozygous CBL mutations in their peripheral blood despite having improved blood counts. Finally, our data provide strong evidence that Cbl is a key negative regulator of Ras signaling networks in hematopoietic cells and it will be important to identify key targets of the Cbl ubiquitin ligase to uncover other biochemical mechanisms involved in growth control. 
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